carbaldehyde O- (3,4-dichlorobenzyl) oxime (CITCO) are selective ligand agonists for mouse (mCAR) (Tzameli et al., 2000) and human CAR (hCAR), respectively (Maglich et al., 2003) .
Several splice variants of hCAR have been identified that are suggested to contribute to functional diversity in CAR responses (Auerbach et al., 2003; Savkur et al., 2003; Jinno et al., 2004; Lamba et al., 2004; DeKeyser et al., 2011) . Among the major splice variants present in the human liver, hCAR2 (SV3 or SV23) and hCAR3 (SV2 or SV24) are estimated to account for up to ~10% and 50% of total hCAR transcripts, respectively (Jinno et al., 2004; Ross et al., 2010) .
Both variants encode proteins containing short insertions within the ligand-binding domain (LBD); i.e., either 4 amino acids (SPTV) for hCAR2 or 5 (APYLT) for hCAR3 (Auerbach et al., 2003) . In comparison to wild-type CAR (herein referred to as hCAR1), these variants exhibit low constitutive activity and appear to function as classic ligand-activated nuclear receptors, although indirect activation mechanisms have been suggested (Faucette et al., 2007; Lau and Chang, 2013) . Limited information also indicates some differences in ligand selectivity among isoforms. While all variants are activated by CITCO (Auerbach et al., 2005; Auerbach et al., 2007; Lau et al., 2011) , hCAR2 is strongly activated by di-(2-ethylhexyl)phthalate (DEHP) (DeKeyser et al., 2009 ) and di-isobutyl phthalate (DeKeyser et al., 2011) , whereas clotrimazole, bisphenol A, and pheniramine (Auerbach et al., 2005; Dring et al., 2010; DeKeyser et al., 2011) are agonists for hCAR3.
Regulation of hCAR by endogenous metabolites has been less well characterized. We previously reported that inhibition of the enzyme squalene synthase with squalestatin 1 (SQ1) induced CYP2B1 expression in rat liver and primary cultured rat hepatocytes (Kocarek et al., 1998) . Further studies demonstrated that this effect was CAR-dependent, independent of reduced sterol synthesis, and mediated through an endogenous isoprenoid (Kocarek and MercerThis article has not been copyedited and formatted. The final version may differ from this version. 
Nr1i3
tm1.1Arte CAR knockout mice (CAR-KO), and C57BL/6-Nr1i3 tm1(NR1I3)Arte humanized CAR transgenic (hCAR-TG) mice (5-6 weeks of age) were purchased from Taconic Farms (Germantown, New York) and maintained in an Association for Assessment and Accreditation of Laboratory Animal Care-approved animal facility with free access to chow and house distilled water for at least one week prior to use. Generation of the hCAR-TG mouse model has been described previously (Scheer et al., 2008) . Briefly, the hCAR (NR1I3) gene sequence from the first coding exon (exon 2) through exon 9 was knocked into the coding region of the murine Nr1i3 gene; therefore expression of hCAR is controlled by the mouse Nr1i3 promoter. Because the entire hCAR genomic coding region is present, all potential major mRNA splice variants of human CAR (hCAR1, hCAR2, hCAR3) (Auerbach et al., 2003; Jinno et al., 2004) are expressed (Scheer et al., 2008) .
Hepatocytes were isolated from mouse livers using a collagenase perfusion method, which has been described in detail elsewhere (Wu et al., 2001) . Following isolation, 1.2 million hepatocytes per well were plated onto collagen I-coated 6-well plates (for RNA experiments), or 0.5 million hepatocytes per well onto 12-well plates (for transfection experiments), and hepatocytes were cultured with Williams' Medium E supplemented with 0.1 μ M triamcinolone acetonide, 0.25 U/ml insulin, 100 U/ml penicillin, and 100 μ g/ml streptomycin. Culture medium was renewed every 24 h and, when appropriate, drugs or synthetic CAR ligands were added to the culture medium as concentrated stock solutions (1000X) diluted in either water (pravastatin, This article has not been copyedited and formatted. The final version may differ from this version. and SQ1), DMSO (CITCO and TCPOBOP), or ETOH (FOH) at concentrations specified in the individual figure legends. FOH (60 uM) and ETOH (0.1%) were complexed to fatty acid-free bovine serum albumin (BSA, 0.05% w/v) in Williams' Medium E for at least ten minutes prior to use.
Total RNA isolation and quantitative reverse transcription polymerase chain reaction (qRT-PCR).
Freshly isolated hepatocytes from CAR-WT, CAR-KO, or hCAR-TG mice were plated onto 6-well plates, as described earlier.
Beginning 24 h after plating, culture medium was replaced with Williams' Medium E containing Matrigel (1 to 50 dilution) and then further incubated overnight at 37°C. The following day, cells were treated with cholesterol synthesis inhibitors or prototypical CAR activators (CITCO, TCPOBOP) at the concentrations described in the individual figure legends. Culture medium containing treatments was renewed once after 24
hours. Forty-eight hours following the initial treatment, total RNA was extracted and column purified using the Purelink RNA isolation kit (Ambion; Carlsbad, CA) and cDNA was synthesized from total RNA using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies; Grand Island, NY), each according to the manufacturer's instructions.
Gene-specific primers to detect murine Cyp2b10, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (Hmgcr), and TATA box binding protein (TBP; product number Mm.PT.39a.22214839) mRNAs as well as the hCAR splice variants hCAR1, hCAR2, and hCAR3 were purchased from Integrated DNA Technologies (IDT; Coralville, IA). Primer sequences to detect the individual splice variants of hCAR have been published previously (Jinno et al., 2004; Zhang et al., 2013) . The sequences (5' to 3') of primer pairs used to detect Cyp2b10 and Hmgcr are as follows: Cyp2b10: forward 5'-GCTTTGAGTACACAGACCGT-3'
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Generation of plasmid constructs. Generation of a CAR-responsive luciferase (firefly)
reporter plasmid containing the phenobarbital-responsive element (PBRE) within a ~2.4 kb of the rat CYP2B1 5'-flanking region has been described previously (Kocarek et al., 1998; Kocarek and Mercer-Haines, 2002) . A CYP2B6 luciferase reporter plasmid containing both the proximal phenobarbital-responsive enhance module (PBREM) and the distal xenobiotic-responsive enhancer module (XREM) of the human CYP2B6 gene (Wang et al., 2003) was generously provided by Dr. Thomas Chang (University of British Columbia; British Columbia, CA).
Expression plasmids containing the full-length coding sequence for the major human CAR splice variants (hCAR1, hCAR2, and hCAR3) and empty vector control were gifts from Dr. Curtis
Omiecinski (Pennsylvania State University; College Park, PA) (Auerbach et al., 2003) .
Isoform-specific hCAR interaction with the coactivator, steroid receptor coactivator (SRC)1 was evaluated using a protein-fragment complementation assay (PCA), as described elsewhere (Remy and Michnick, 2006; Remy and Michnick, 2007) . Expression plasmids Results.
Effect of SQ1 treatment on Cyp2b10 and Hmgcr mRNA levels in primary cultured
hepatocytes isolated from CAR-WT and CAR-KO mice. To determine whether the effect of squalene synthase inhibition on isoprenoid-mediated CYP2B expression is conserved and further investigate whether this effect is due to activation of one or more of the hCAR isoforms that are generated by alternative splicing, we first evaluated treatment effects on Cyp2b10 mRNA levels in primary hepatocytes isolated from wild-type (CAR-WT) and CAR-KO mice. As shown in To demonstrate that SQ1 and pravastatin were both effective in blocking cholesterol synthesis, we evaluated Hmgcr mRNA levels in wild-type and CAR-KO hepatocytes ( whereas pravastatin had no effect on Cyp2b10 mRNA levels. Consistent with the effects This article has not been copyedited and formatted. The final version may differ from this version. observed in wild-type mouse hepatocytes, SQ1 and pravastatin also increased Hmgcr mRNA levels to a similar extent (P<0.05; Fig. 2B ), demonstrating that both treatments were equally effective in blocking sterol synthesis and the cumulative effect of SQ1 was due to isoprenoid accumulation. Relative mRNA levels for the major splice variants of hCAR were also assessed ( Fig 2C) . We found that among the major splice variants, hCAR1 (SV0; 59%) was most abundantly expressed, followed by hCAR3 (~33%) and hCAR2 (~8%), when expressed as a percentage of the total of the three isoforms. These results are consistent with levels observed in human livers and other hCAR transgenic mouse models (Jinno et al., 2004; Ross et al., 2010; Zhang et al., 2013) .
SQ1 activates CYP2B1-PBRE and CYP2B6-PBREM/XREM reporter activity in an
hCAR1-dependent manner. The previous results suggested that SQ1 treatment could activate hCAR depending on the cellular context. Therefore, we next evaluated whether the effects of SQ1 were mediated through one or more of the individual splice variants of hCAR using hepatocytes from a CAR-KO cellular background. To consider whether species differences in CAR target gene sequences could contribute to hCAR-mediated effects, luciferase reporter assays were conducted with constructs containing either the PBREM/XREM of the human CYP2B6 gene or the PBRE of the rat CYP2B1 gene. Primary hepatocytes isolated from CAR-KO mice were co-transfected with a reporter construct and each individual hCAR expression plasmid or an empty vector control, and treatment effects were evaluated after 48 h. Results are presented in Fig. 3 . For both CYP2B reporter plasmids, a significant interaction was detected between treatment and expression plasmid (P<0.0001). In general, transfection of cells with hCAR1 significantly increased basal activity of both reporters, as compared to the empty This article has not been copyedited and formatted. The final version may differ from this version. Fig. 3A and 3B).
Some treatment-induced increases in luciferase activity for both reporters were evident in the empty expression vector-transfected CAR-KO hepatocytes, which were stronger for CITCO than the other treatments and somewhat variable among different hepatocyte preparations. In cells transfected with the CYP2B1 reporter, CITCO treatment significantly increased luciferase activity in the hCAR3-transfected cells (Fig. 3A) . However, this CITCO-mediated increase was not significantly different from the luciferase activity measured in CITCO-treated empty vector controls (P>0.05), indicating a weak effect of CITCO/hCAR3 on CYP2B1 activation in this system. After adjusting for background levels in the empty expression vector-transfected controls and the basal activity in vector-matched untreated controls, the adjusted fold-changes for hCAR1 were 1.5, 1.5, and 2.4; for hCAR2 were 0.95, 0.87, and 1.1; and for hCAR3 were 1.0, 1.0, and 1.0 in hepatocytes treated with SQ1, CITCO, and PB, respectively. In cells transfected with the CYP2B6-PBREM/XREM reporter, significant basal luciferase activity was detected with all hCAR isoforms, although this effect was weaker for the hCAR2 and hCAR3 isoforms (<2-fold) than for hCAR1 (~6-fold) (Fig. 3B) . Similar to the findings for the CYP2B1 reporter, CITCO or SQ1 treatment increased CYP2B6-PBREM/XREM reporter activity <2-fold in hCAR2 or hCAR3-transfected hepatocytes, and more strongly in hCAR1-transfected cells. After adjusting for basal activity detected among the different hCAR expression plasmids and for treatment effects within the empty vector controls, the adjusted fold-changes for hCAR1 were 1.4, 2.7, and 2.3; for hCAR2 were 1.0, 1.1, and 1.1; and for hCAR3 were 1.1, 1. Therefore we additionally determined whether FOH treatment could directly influence hCAR1-or mCAR-mediated activation of the CYP2B6-PBREM/XREM reporter plasmid. As shown in Assay (Fig. 6) and isoprenoid alcohols (geranylgeraniol) were also tested for their abilities to bind to hCAR1, and all showed little or no ability to bind (Fig. 6) , although at the highest concentrations tested, geranylgeraniol and methyl farnesoate showed slight trends toward agonist-type binding, while FPP and geranylgeranyl pyrophosphate showed slight trends toward inverse agonist-type binding.
Discussion.
Nonsterol isoprenoids are intermediates produced in the cholesterol biosynthetic pathway that serve as substrates for prenylation reactions and are precursors for a number of important cellular products (Edwards and Ericsson, 1999) . FOH and geranylgerianol, in particular, are biologically active molecules that can influence the expression of drug-and lipid-metabolizing enzymes through modulation of nuclear receptor signaling pathways (Kocarek and MercerHaines, 2002; Takahashi et al., 2002; Goto et al., 2011a) . We previously reported that accumulation of isoprenoids in response to squalene synthase inhibition increased CYP2B1 expression in primary rat hepatocytes in a CAR-dependent manner (Kocarek et al., 1998; Kocarek and Mercer-Haines, 2002) . In continuation of these studies, we investigated whether mCAR or any of the major hCAR isoforms are activated by similar mechanisms. Using primary hepatocytes from wild-type, CAR-KO, and hCAR-TG mice, we found that squalene synthase inhibition significantly induced Cyp2b10 mRNA levels in mCAR-or hCAR-expressing hepatocytes, whereas this effect was attenuated in the absence of CAR. Consistent with previous findings (Kocarek and Reddy, 1996) , pravastatin had no effect on Cyp2b10 expression, although both pravastatin and SQ1 induced Hmgcr mRNA to a similar extent. These findings indicate that the main effects of SQ1 on Cyp2b10 induction are mediated through CAR, and that both human and murine CAR are activated by endogenous isoprenoids.
The splice variants hCAR2 and hCAR3 are estimated to account for up to ~10 and 50% of total hCAR transcripts in human liver (Jinno et al., 2004; Zhang et al., 2013) , respectively, which was corroborated in the current study. The amino acid insertion into hCAR2 is predicted to alter CAR's ligand-binding pocket, thereby modifying the activation profile (DeKeyser et al., 2009 ). In comparison, ligand selectivity of hCAR3 is similar to that of the reference receptor (Omiecinski et al., 2011 ). In the current study, we evaluated the hCAR isoforms for the ability to activate CYP2B reporter activity and found that the effects of SQ1 were mediated primarily in an hCAR1-dependent manner. The normalized activation of hCAR1 by SQ1 was significant and isoprenoids may still influence activity of other hCAR isoforms, although, at least in the primary mouse hepatocyte model, this does not strongly activate CYP2B transcription. Given the relatively high expression of the major hCAR isoforms in human liver, future studies focusing on differences in global gene regulation between isoforms would be useful to determine whether there are more isoform-selective target genes and/or additional elements necessary for stronger transactivation.
In conclusion, results from the current study extend on previous findings and indicate that FPP-derived isoprenoids activate CAR-mediated CYP2B responses, further linking cholesterol biosynthesis to CAR regulation among different species. Additional findings from coactivator recruitment assays further suggest that the effect of isoprenoids on mediating CAR responses occurs in an indirect manner. Endogenous isoprenoid levels are known to be influenced by a number of pharmaceutical drugs including squalene synthase inhibitors, N-bisphosphonates, as well as statins (Park et al., 2014) . Therefore, our findings have implications for future studies aimed at evaluating the biological effects of these compounds on CAR-mediated signaling pathways as well as understanding species differences on hepatocellular physiology.
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